ir.avantorinc.comAvantor - Investor Relations

Skip to main content Overview About us Mission, vision, values Leadership Services History Global footprint Corporate social responsibility Thought leadership News Careers Governance Brands NuSil™ J.T.Baker® VWR®, part of Avantor Macron Fine Chemicals™ Puritan Products™ BeneSphera™ RANKEM™ POCH™ Industries Biopharma Healthcare Education Advanced technologies & applied materials Services Lab & production services Clinical services Procurement & sourcing services Equipment services Commercial kitting & services Digital solutions Downstream optimization services The journey of a drug Our offerings Materials and consumables Equipment and instrumentation Avantor Services Solutions supporting Covid-19 Services & specialty procurement Working with Avantor How to buy How to ship How to sell Innovation at avantor Quality and compliance Management of change Careers Investors News & Events News Events & Presentations Financials Annual Reports Quarterly Results SEC Filings Governance Avantor Leadership Board of Directors Committee Composition Governance Charters & Guidelines Governance & Integrity Avantor Code of Ethics & Conduct Stock Information Analyst Coverage Historical Stock Quote Stock Chart Stock Quote Corporate Social Responsibility menu Toggle navigation Certificate/SDS search Buy from VWR Update to Avantor’s response to the coronavirus (COVID-19) pandemic Investor Relations Overview About us Mission, vision, values Leadership Services History Global footprint Corporate social responsibility Thought leadership News Careers Governance Brands NuSil™ J.T.Baker® VWR®, part of Avantor Macron Fine Chemicals™ Puritan Products™ BeneSphera™ RANKEM™ POCH™ Industries Biopharma Healthcare Education Advanced technologies & applied materials Services Lab & production services Clinical services Procurement & sourcing services Equipment services Commercial kitting & services Digital solutions Downstream optimization services The journey of a drug Our offerings Materials and consumables Equipment and instrumentation Avantor Services Solutions supporting Covid-19 Services & specialty procurement Working with Avantor How to buy How to ship How to sell Innovation at avantor Quality and compliance Management of change Careers Investors News & Events News Events & Presentations Financials Annual Reports Quarterly Results SEC Filings Governance Avantor Leadership Board of Directors Committee Composition Governance Charters & Guidelines Governance & Integrity Avantor Code of Ethics & Conduct Stock Information Analyst Coverage Historical Stock Quote Stock Chart Stock Quote Corporate Social Responsibility Overview About us Mission, vision, values Leadership Services History Global footprint Corporate social responsibility Thought leadership News Careers Governance Brands NuSil™ J.T.Baker® VWR®, part of Avantor Macron Fine Chemicals™ Puritan Products™ BeneSphera™ RANKEM™ POCH™ Industries Biopharma Healthcare Education Advanced technologies & applied materials Services Lab & production services Clinical services Procurement & sourcing services Equipment services Commercial kitting & services Digital solutions Downstream optimization services The journey of a drug Our offerings Materials and consumables Equipment and instrumentation Avantor Services Solutions supporting Covid-19 Services & specialty procurement Working with Avantor How to buy How to ship How to sell Innovation at avantor Quality and compliance Management of change Careers Investors News & Events News Events & Presentations Financials Annual Reports Quarterly Results SEC Filings Governance Avantor Leadership Board of Directors Committee Composition Governance Charters & Guidelines Governance & Integrity Avantor Code of Ethics & Conduct Stock Information Analyst Coverage Historical Stock Quote Stock Chart Stock Quote Corporate Social Responsibility Setting science in motion to create a better world Avantor ® , a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. Avantor’s differentiated and highly resilient business model positions the company to deliver results across market segments. We are progressing a long-term growth strategy based on product innovation, expansion in emerging markets and targeted M&A. From FORTUNE. © 2020 FORTUNE Media IP Limited All rights reserved. Used under license. FORTUNE is a registered trademark of FORTUNE Media IP Limited and is used under license. FORTUNE and FORTUNE Media IP Limited are not affiliated with and do not endorse products or services of, Avantor. Why Avantor Our offerings are powering innovation from scientific discovery to scale-up and commercial delivery. We further embed ourselves in our customers’ workflows through our robust service capabilities. The strengths of our model include, high recurring revenues, customized solutions, robust ecommerce platform, strong cash flow generation, enduring customer relationships and subject matter expertise. Spotlight We have deep ties to the scientific and pharma industries and are supporting key breakthroughs and life-changing treatments for patients. Biopharma accounts for more than 50% of our revenue. Our portfolio of nearly 6 million different products is used in virtually every stage of the most important research, development and production work, such as monoclonal antibodies, cell and gene therapy, vaccines . Our products are specified in more than 80% of the top 20 biologic drugs and we serve each of the world’s top 10 medical device companies. Our strength in biopharma is underscored by the crucial role we are playing in the fight against the COVID-19 pandemic. 2019 Financial Summary Business mix How we go to market Avantor today $6.04B Revenue Organic Net Sales Growth 5.1% ~$1.03B Adj. EBITDA Growth of 9.1% $0.58 Adjusted EPS Growth of 61.8% $302.4M Free Cash Flow Growth of ~24% 1 5 % 4 0 % 3 0 % 1 5 % 1 5 % 10% 5 0% 2 5 % 19 28 9 Strong conversion of revenue growth to EBITDA, driving strong margin expansion. -- We expanded our adjusted EBITDA margins ~100 basis points by successfully managing our product pricing relative to COGS inflation, growing high margin proprietary materials and consumables offerings by high single digits, and realizing the productivity benefits of the VWR integration synergies. Solid operational execution, strong free cash flow generation resulting in continued deleveraging and tax initiatives drove adjusted EPS to $0.58. We are pleased with our pace of deleveraging and the reduction in our cost of debt. We generated $302 million in free cash flow, a $140 million increase (or 86%) from 2018. During 2019, we reduced debt outstanding by $1.9 billion. Our global infrastructure strategically positions us close to our customers and gives us the resources and agility to serve more than 225,000 customer locations in more than 180 countries, promoting extensive access to research scientists around the world. Well-developed North American market. Region includes Canada, Latin America, USA and comprises 59% of our 2019 revenue. Strong presence in Europe with offices in 19 countries to serve customers across the region and comprises 35% of our 2019 revenue. Well-positioned in the developed markets we serve, with expanding infrastructure and footprint in Asia,...